Milestone Pharmaceuticals Inc. (MIST)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound
Milestone Pharmaceuticals remains a 'Sell' due to weak CARDAMYST differentiation and poor commercial uptake versus low-cost generics. MIST's Q2 revenue was just $559K on over 1,200 scripts, reflecting heavy discounting and minimal payer coverage, with only ~20% of the PSVT market covered. Financial health is deteriorating: $170M cash, $39M 1H burn, liabilities doubled to $163M, and equity fell to $18M amid high SG&A and compounding royalty debt.
Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript
Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript
Milestone Pharmaceuticals Q2 Earnings Call Highlights
Milestone Pharmaceuticals NASDAQ: MIST reported early commercial traction for CARDAMYST following its mid-February launch, while advancing a pivotal Phase III study of etripamil in atrial fibrillation with rapid ventricular rate, or AFib-RVR.
Milestone Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 38,242 | $140,871.3 | $46,655.24 | -$94,216.06 | -66.88% |
 Point72 Asset Management LP Point72 Asset Management LP | 5.41M | $7.49M | $5.95M | -$1.54M | -20.51% |
 Didric Cederholm Lion Point Capital LP | 820,000 | $1.46M | $902,000 | -$553,229.78 | -38.02% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 15,000 | $30,300 | $16,650 | -$13,650 | -45.05% |
 Christian Keedy Guardian Wealth Advisors LLC / Nc | 339,450 | $626,485.5 | $373,395 | -$253,090.5 | -40.4% |
Milestone Pharmaceuticals Inc. (MIST) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Milestone Pharmaceuticals Inc. ever had a stock split?
Milestone Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Joseph G. Oliveto CEO | NASDAQ (NGS) Exchange | 59935V107 CUSIP |
| CA Country | 38 Employees | - Last Dividend | - Last Split | 9 May 2019 IPO Date |
Overview
Milestone Pharmaceuticals Inc. is a biopharmaceutical company that concentrates its efforts on the innovation and commercialization of cardiovascular medicines. Established in 2003 and based in Montréal, Canada, the company is engaged in addressing unmet medical needs in cardiovascular diseases with a strong focus on developing novel therapeutic solutions. Milestone Pharmaceuticals has forged partnerships through its license and collaboration agreement with Ji Xing Pharmaceuticals for the development and commercialization of its lead product candidate etripamil across various applications, alongside collaborative efforts with the Montreal Heart Institute, the WCN network, and other leading research centers.
Products and Services
Milestone Pharmaceuticals Inc. is primarily focused on the development of its flagship product candidate, etripamil, alongside its engagement in various collaborative research efforts:
- Etripamil: A potent novel calcium channel blocker currently undergoing extensive clinical trials for the treatment of cardiovascular conditions. The applications of etripamil include:
- Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, focusing on addressing this acute and disruptive heart condition effectively.
- Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate (AF and RVR), representing a concerted effort to expand its application in managing other critical cardiac arrhythmias.
- Collaborations: Milestone Pharmaceuticals has entered into various strategic partnerships to bolster the development and commercialization potential for etripamil across different therapeutic and prophylactic uses:
- License and collaboration agreement with Ji Xing Pharmaceuticals, aimed at exploring and advancing etripamil's prophylactic and therapeutic applications for human use.
- Research partnerships with the Montreal Heart Institute, the WCN network, and additional research centers, facilitating a broad base of clinical support and validation for etripamil's efficacy and safety in treating cardiovascular diseases.
